Immunotherapy with guts: a review of microbial therapeutic adjuncts for immunotherapy in solid tumors
The Oncologist · 08.05.2026 · 31 (6)
DOI: 10.1093/oncolo/oyag131 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Oncologist, online erschienen am 09.04.2026. Verfasst von Kelly Pum und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Biological Sciences, University of Minnesota, Minneapolis, MN, 55108, United States. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Fecal Microbiota Transplantation, Gastrointestinal Microbiome. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Minnesota Colorectal Cancer Foundation and The Mezin-Koats Foundation.
Abstract (Originalsprache)
Background
Immunotherapy has transformed the management of some solid tumor types, but its impact has been limited to the subset of cancer patients who have “hot” or immunogenic tumors. Num2erous studies are based on strategies for turning “cold,” or immune-unresponsive, tumors into a “hot” state. The gut microbiome has emerged as a potential co-therapy for standard immune checkpoint inhibitors (ICIs) to achieve this goal. Recent approaches have primarily focused on the use of probiotics, microbial consortia, or fecal microbiota transplantations in combination with anti-PD-1 and anti-CTLA-4 antibodies.
Methods
This review highlights the current status of microbiome modulation and its potential impact on clinical practice. Probiotics, such as CMB588, and microbial consortia have been selected following successful preclinical studies. These taxa may initiate T cell infiltration and are commonly found in the microbial profiles of individuals who have previously responded to immunotherapy.
Results
Several trials with these therapies have had success and noted minimal safety concerns compared to monotherapy treatments. Fecal microbiota transplantation (FMT), originally used to treat Clostridium difficile infections, has also demonstrated promising results in increasing immune checkpoint inhibitor (ICI) efficacy across various cancer types and is being utilized in multiple ongoing trials.
Conclusion
These therapeutics form the foundation for exciting possibilities in immunotherapy and improving patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Biological Sciences, University of Minnesota, Minneapolis, MN, 55108, United States.
- Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, MN, 55455, United States.
- Masonic Cancer Center, University of Minnesota Medical School, Minneapolis, MN, 55455, United States.
- Department of Surgery, University of Minnesota Medical School, Minneapolis, MN, 55455, United States.
- Center for Immunology, University of Minnesota Medical School, Minneapolis, MN, 55455, United States.
ORCID-Profile: Kelly Pum, Emil Lou, Paolo Goffredo, Cyrus Jahansouz, Subbaya Subramanian, Ajay Prakash
Förderung
- NCI NIH HHS
- Minnesota Colorectal Cancer Foundation and The Mezin-Koats Foundation
Zitieren
APA
Pum, K., Lou, E., Goffredo, P., Jahansouz, C., Subramanian, S., & Prakash, A. (2026). Immunotherapy with guts: a review of microbial therapeutic adjuncts for immunotherapy in solid tumors. The Oncologist, 31(6). https://doi.org/10.1093/oncolo/oyag131
Vancouver
Pum K, Lou E, Goffredo P, Jahansouz C, Subramanian S, Prakash A. Immunotherapy with guts: a review of microbial therapeutic adjuncts for immunotherapy in solid tumors. The Oncologist. 2026;31(6). doi:10.1093/oncolo/oyag131
BibTeX
@article{Pum2026,
author = {Pum, Kelly and Lou, Emil and Goffredo, Paolo and Jahansouz, Cyrus and Subramanian, Subbaya and Prakash, Ajay},
title = {Immunotherapy with guts: a review of microbial therapeutic adjuncts for immunotherapy in solid tumors},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {6},
doi = {10.1093/oncolo/oyag131}
}
EUVIMED